Tunheim G, Baranowska-Hustad M, Lund-Johansen F, Fossum E, Bhandari S, Kukule L, Møller TKR, Vikse EL, Bekkevold T, Oftung F, Robertson AH, Næss LM(2025) SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway APMIS, 133(12), e70102 DOI 10.1111/apm.70102, PubMed 41376258
Aamodt AH, Ueland T, Boldingh M, Bezgal BE, Argren MB, Dunne CA, Otterdal K, Gregersen I, Bjerkeli V, Michelsen AE, Husøy A, Morsund ÅH, Devik K, Poole AC, Gjendemsjø KB, Schlüter K, Mathisen SM, Aalstad-Johansen M, Skattør TH, Sønnervik J, Boye TB, Popperud TH, Høgestøl EA, Harbo HF, Lund-Johansen Fet al.(2025) Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2 infection and vaccination BMJ Neurol Open, 7(2), e001013 DOI 10.1136/bmjno-2024-001013, PubMed 40881041
Eggebø MS, Heinzelbecker J, Palashati H, Chandler N, Tran TT, Li Y, Yang W, Laos M, Blaas I, Rustad EH, Bollineni RC, Delic-Sarac M, Lund-Johansen F, Nielsen MM, Olweus J(2025) TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors Nat Immunol, 26(10), 1726-1736 DOI 10.1038/s41590-025-02252-1, PubMed 40866620
Contact information: Group leader Fridtjof Lund-Johansen, Department of Immunology, Oslo University Hospital, Rikshospitalet, Tel: +47 23073016, E-mail: fridtjof.lund-johansen@rr-research.no
